TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

Shares of Cybin, Inc. ($CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the ...

Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown potential as a treatment for major depressive disorder (MDD), and other severe ...

Cybin has reported 71% remission in patients with major depressive disorder (MDD) who received two doses of the psilocin ...

Most people want less anxiety. The goal is to actually have realistic anxiety levels. Here, I explain how to attain realistic ...

Mental health, a topic that sends chills down the spine, is no longer a phenomenon that ‘happens to others’. According to the ...

The company's lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder (“PTSD”) and stress-induced anxiety disorders. SP-26 is a time-release, ketamine-loaded implant ...

Hometown NP, co-founded by Dr. Chime Ajiere, DNP, in 2023, is a leading telehealth practice specializing in telepsychiatric ...